Original ReportValidation of the Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) in Acute Low Back Pain
Key words
Cited by (0)
Support for the clinical trial from which the data analyzed in this article were derived was provided by Janssen Scientific Affairs, which also provided a research grant to Analgesic Solutions to support data analyses and publication preparation.
Permission to use the SF-MPQ-2 can be obtained from the Mapi Research Trust, Lyon, France (e-mail: [email protected]; website: www.proqolid.com). Dr. Ronald Melzack and the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the U.S. Food and Drug Administration share licensing fees from for-profit organizations using the SF-MPQ-2 in their research. R.H.D. has received in the past 12 months a research grant from the U.S. Food and Drug Administration (grant no. U01FD004187) and compensation for activities involving clinical trial research methods from Acetylon, Astellas, AstraZeneca, Avanir, Axsome, Biogen, Centrexion, Charleston, Chromocell, Daiichi-Sankyo, Eli Lilly, Hydra, Johnson & Johnson, Lpath, Maxwell Biotech, Metys, Olatec, Phosphagenics, QRx, Relmada, Salix, Sorrento, Spinifex, Teva, and Virobay. D.C.T. has received in the past 12 months a research grant from the U.S. Food and Drug Administration (grant no. U01FD004187) and consulting fees or honoraria in the past year from Lilly, Mallincrodt, Orexo, Ortho-McNeil Janssen, Pfizer, and Xdynia. J.J.T. was a full-time employee of Analgesic Solutions at the time the study was conducted and the first draft of the manuscript was prepared. D.M.B., M.K., and C.B. are full-time employees of Johnson & Johnson. N.P.K. is the owner of Analgesic Solutions.